Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.

Lepretre, Stephane;Aurran, Therese;Mahé, Beatrice;Cazin, Bruno;Feugier, Pierre;et.al.
(2012) Blood — Vol. 119, n° 22, p. 5104-5110 (2012)

Files

No attached file found for this publication.

Details

Authors
  • Lepretre, Stephane
    Author
  • Aurran, Therese
    Author
  • Mahé, Beatrice
    Author
  • Cazin, Bruno
    Author
  • Feugier, Pierre
    Author
Show more
Abstract
A French and Belgian multicenter phase 3 trial was conducted in medically fit patients with untreated chronic lymphocytic leukemia. Of 178 patients enrolled in the study, 165 were randomly assigned to receive 6 courses of oral fludarabine and cyclophosphamide (FC) in combination with rituximab (FCR; 375 mg/m(2) in cycle one, 500 mg/m(2) in all subsequent cycles) or alemtuzumab (FCCam; 30 mg subcutaneously injected on cycle days 1-3); each cycle was 28 days. Recruitment was halted prematurely because of excess toxicity; 8 patients died in the FCCam group, 3 from lymphoma and 5 from in-fection. Overall response rates were 91% with FCR and 90% with FCCam (P = .79). Complete remission rates were 33.75% with FCR and 19.2% with FCCam (P = .04). Three-year progression-free survival was 82.6% with FCR and 72.5% with FCCam (P = .21). Three-year overall survival was similar between the 2 arms at 90.1% in the FCR arm and 86.4% in the FCCam arm (P = .27). These results indicate that the FCCam regimen for the treatment of advanced chronic lymphocytic leukemia was not more effective than the FCR regimen and was associated with an unfavorable safety profile, representing a significant limitation of its use. This study is registered with www.clinicaltrials.gov as number NCT00564512.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Lepretre, S., Aurran, T., Mahé, B., Cazin, B., Tournilhac, O., Maisonneuve, H., Casasnovas, O., Delmer, A., Leblond, V., Royer, B., Corront, B., Chevret, S., Delépine, R., Vaudaux, S., Van Den Neste, E., Béné, M. C., Letestu, R., Cymbalista, F., & Feugier, P. (2012). Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood, 119(22), 5104-5110. https://doi.org/10.1182/blood-2011-07-365437 (Original work published 2012)